The University Court of the University of Glasgow Patent applications |
Patent application number | Title | Published |
20150272984 | AGENTS FOR THE PREVENTION AND/OR TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE - The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage. | 10-01-2015 |
20140234263 | CELLULAR AND MOLECULAR THERAPIES - The present invention provides, among other things, improved compositions and methods for the treatment of tissue damage (e.g., acute or chronic) and related diseases, disorders or conditions based on the use of pathfinder cells, extracellular secretomes thereof, and/or pathfinder cell-associated microRNAs. In some embodiments, the present invention provides a method for treating tissue damage (e.g., acute or chronic) comprising a step of administering a population of cells to an individual suffering from a disease, disorder or condition characterized by acute damage to one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce tissue repair, regeneration, remodeling, reconstitution or differentiation. In some embodiments, the present invention provides a method for treating inflammation comprising a step of administering a population of cells, or extracellular secretomes thereof, to an individual suffering from a disease, disorder or condition characterized by inflammation of one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce an anti-inflammatory response. | 08-21-2014 |
20140163086 | Methods of Modulating MicroRNAs in the Treatment of Pulmonary Arterial Hypertension - The present invention provides a method of treating or preventing pulmonary arterial hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitors for treating pulmonary arterial hypertension are also disclosed. | 06-12-2014 |
20130337010 | REASSORTANT BTV AND AHSV VACCINES - The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV. | 12-19-2013 |
20130209439 | INHIBITORS OF PDE4 BINDING TO HSP20 - The present invention provides methods and materials for use in increasing HSP20 activation in a biological system, for example by increasing phosphorylation of Ser16 of HSP20. In one aspect, the invention provides a method for increasing HSP20 activation in a biological system, comprising contacting the system with an antagonist capable of inhibiting PDE4 binding to HSP20, the antagonist comprising or consisting essentially of a fragment of PDE4 or an analogue thereof. In a further aspect the invention provides a method of screening for an agent able to increase activation of HSP20. A preferred antagonist has a C-terminal lysine residue. | 08-15-2013 |
20130143314 | THERAPEUTIC USES OF MICROVESICLES AND RELATED MICRORNAS - The present invention provides improved methods and compositions based on microvesicles for the treatment of various diseases, disorders and conditions. In particular, the present invention encompasses the recognition that microvesicles contain specific microRNAs which may function as intercellular regulators involved in cell or tissue regeneration, remodeling, reconstruction, reprogramming or transdifferentiation. Thus, among other things, the present invention provides methods and compositions based on microvesicles and/or associated microRNAs that provide more predictable and effective therapeutic results. | 06-06-2013 |
20120219507 | METHOD OF DETERMINING METABOLIC FUNCTION - The present invention provides a novel lactate difference imaging (LDI) technique, allowing assessment of the metabolic responses of tissue over a period of time. This approach utilises lactate change over a time period as an indicator of viable tissue, and offers benefits in the management and treatment of the effects of many common diseases, in particular stroke. | 08-30-2012 |
20120213664 | PLASMA GENERATION AND USE OF PLASMA GENERATION APPARATUS - A plasma generating apparatus comprises a first, powered electrode and a second electrode structure located in front of the first electrode. An insulating layer is interposed between the first electrode and the second electrode structure. The second electrode structure has a plurality of second electrode portions defining gap portions therebetween. The width of the gap portions is w. The second electrode portions each have a forward surface and the gap portions each having a forward surface, the height difference between the forward surface of each second electrode portion and the forward surfaces of the adjacent gap portions being h, and wherein h is at most 1 mm and the ratio w/h is at least 1. Thus, the forward surfaces of the second electrode portions and the forward surfaces of the gap portions together provide a smooth topography. The plasma generated by the apparatus (in air or other oxygen-containing gas) forms ozone, which can be used to treat foodstuffs, for example. The smooth topography allows substantially all of the plasma to be generated inside a package whose wall is pressed towards the second electrode structure. | 08-23-2012 |
20120149126 | Fluidics Apparatus and Fluidics Substrate - A fluidics apparatus is disclosed for manipulation of at least one fluid sample, typically in the form of a droplet. The apparatus has a substrate surface with a sample manipulation zone for location of the fluid sample. A transducer arrangement such as an interdigitated electrode structure on a piezoelectric body provides surface acoustic waves at the substrate surface for manipulation of the fluid sample. The substrate surface has an arrangement of surface acoustic wave scattering elements forming a phononic crystal structure for affecting the transmission, distribution and/or behaviour of surface acoustic waves at the substrate surface. Also disclosed is a method for lysing a cell. In this method, the cell is comprised in a fluid sample contacting a substrate surface, the method comprising providing surface acoustic waves at the substrate surface, such that the cell lyses. | 06-14-2012 |
20120129788 | PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER - The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer. | 05-24-2012 |
20120065148 | PHOSPHODIESTERASE 4D7 AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor. | 03-15-2012 |
20120065100 | PHOSPHODIESTERASE 9A AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer. | 03-15-2012 |
20110172106 | Detection of Interactions Between Lipid Complexes and Lipid Binding Agents - The invention relates to materials and methods for detecting interactions between lipid complexes and lipid binding agents. More specifically, the invention provides materials and methods for displaying lipid complexes, particularly those containing two or more different lipid molecules, on a hydrophobic surface so as to mimic their in vivo environment more closely than in other analytical methods. This allows more accurate detection of lipid complexes and even identification of lipid complexes which are not detected by other methods. The invention lends itself particularly well to array or microarray formats. | 07-14-2011 |
20110158961 | MATERIALS AND METHODS RELATING TO CELL BASED THERAPIES - The invention relates to the provision of a novel cell population that can be used for tissue regeneration and the treatment of disease states associated with cell degeneration for age related tissue changes. The cell population are derived from adult stem/progenitor cells which are characterised by being positive or negative to the Thy1.1 cell marker. | 06-30-2011 |
20110157599 | Uses of Electromagnetic Interference Patterns - Various uses of visible light interference patterns are provided. Suitable interference patterns are those formed by diffraction from patterns of apertures. Typical uses disclosed herein relate to spatial metrology, such as a translational and/or angular position determination system. Further uses include the analysis of properties of the light itself (such as the determination of the wavelength of the electromagnetic radiation). Still further uses include the analysis of one or more properties (e.g. refractive index) of the matter through which the light passes. Part of the interference pattern is captured at a pixellated detector, such as a CCD chip, and the captured pattern compared with a calculated pattern. Very precise measurements of the spacing between maxima is possible, thus allowing very precise measurements of position of the detector in the interference pattern. | 06-30-2011 |
20100218819 | SEMICONDUCTOR OPTOELECTRONIC DEVICES AND METHODS FOR MAKING SEMICONDUCTOR OPTOELECTRONIC DEVICES - A semiconductor-based optoelectronic device such as a solar cell has an n-type layer and a p-type layer, together forming a p-n junction. Contact regions are formed on the device, with light-receiving regions between contact regions. A window layer is formed over the n-type layer or the p-type layer at the light-receiving region, the window layer promoting reduced carrier recombination at the surface of the n-type or p-type layer, and/or reflection of minority carriers in the n-type or p-type layer towards the p-n junction. The device has a window protection layer formed over the window layer, the window protection layer providing protection from degradation of the window layer during manufacture and/or operation of the device. For GaAs-based devices the window layer may be Al0.9Ga0.1As and the window protection layer may be GaAs. Additionally, an AlAs etch stop layer may be provided over the window protection layer. | 09-02-2010 |
20090030293 | SENSING DEVICE, APPARATUS AND SYSTEM, AND METHOD FOR OPERATING THE SAME - A sensing device, apparatus and system, and method for operating the same are provided. The sensing apparatus includes a first module and a second module. The first module includes a controller, a transmitter and an array of sensor elements. The controller is capable of activating one or more sensor elements in the array independently of others in the array, in order to obtain a sensor output from the array at different times by using different sensor elements in said array. The transmitter is configured to transmit sensor data derived from the sensor output from the first module to a receiver of the second module. Each sensor element is a biological sensor for detecting the presence of the same analyte in the environment in which the sensor array is to be deployed. | 01-29-2009 |